title: Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.
abstract: We reviewed the evolution of the methods used in cost-effectiveness analyses of granulocyte colony-stimulating factors (G-CSFs) in the primary and secondary prevention of febrile neutropenia (FN) in patients receiving myelosuppressive cancer chemotherapy. Areas covered: FN is a side effect of myelosuppressive chemotherapy associated with significant morbidity, mortality, and costs. The risk of FN may depend on the drugs used within a chemotherapy regimen, and an FN event may cause chemotherapy dose reductions or delays in subsequent cycles. Expert commentary: More recent pharmacoeconomic models have reflected these clinical observations by modeling sequential chemotherapy regimens to account for FN risk on a per-cycle basis, and by accounting for chemotherapy dose reductions and consequent survival losses.
authors.affiliation: a Health Economics & Outcomes Research, Optum , Boston , MA , USA.
authors.forename: Kelly
authors.initials: K
authors.lastname: Fust
authors.affiliation: a Health Economics & Outcomes Research, Optum , Boston , MA , USA.
authors.forename: Anju
authors.initials: A
authors.lastname: Parthan
authors.affiliation: b Health Economics & Outcomes Research, Optum , Burlington , ON , Canada.
authors.forename: Michael
authors.initials: M
authors.lastname: Maschio
authors.affiliation: a Health Economics & Outcomes Research, Optum , Boston , MA , USA.
authors.forename: Qing
authors.initials: Q
authors.lastname: Gu
authors.affiliation: c Global Health Economics , Amgen Inc ., Thousand Oaks , CA , USA.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Li
authors.affiliation: d Public Health Sciences Division and Clinical Research Divisions , Fred Hutchinson Cancer Research Center , Seattle , WA , USA.
authors.forename: Gary H
authors.initials: GH
authors.lastname: Lyman
authors.affiliation: c Global Health Economics , Amgen Inc ., Thousand Oaks , CA , USA.
authors.forename: Spiros
authors.initials: S
authors.lastname: Tzivelekis
authors.affiliation: e Global Health Economics , Amgen (Europe) GmbH , Zug , Switzerland.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Villa
authors.affiliation: f Department of Health Policy and Management; Department of Biostatistics , Harvard T.H. Chan School of Public Health , Boston , MA , USA.
authors.forename: Milton C
authors.initials: MC
authors.lastname: Weinstein
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D003362:Cost-Benefit Analysis; D064147:Febrile Neutropenia / Q000139:chemically induced / Q000191:economics / Q000517:prevention & control*; D016179:Granulocyte Colony-Stimulating Factor / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D018803:Models, Economic; D009369:Neoplasms / Q000188:drug therapy; D011322:Primary Prevention / Q000191:economics / Q000379:methods; D055502:Secondary Prevention / Q000191:economics / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor
keywords: Febrile neutropenia; cost-effectiveness; economic evaluation; growth-colony stimulating factors; review